Comparative Efficacy and Safety of Saroglitazar and Dapagliflozin on Hepatic Steatosis and Glycemic Control in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease: A 25‐Week Prospective Multicenter Comparative Cohort Study
ABSTRACT Introduction Metabolic dysfunction‐associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease globally, driven by rising obesity and type 2 diabetes mellitus (T2DM). Existing medications provide minimal fibrosis regression, highlighting the need for comparative evidence on agents...